New insider Smith Beth Ann claimed ownership of 7,889 shares (SEC Form 3)
$MGNX
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 01/02/2025 |
3. Issuer Name and Ticker or Trading Symbol
MACROGENICS INC [ MGNX ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock | 7,889 | D | |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Employee Stock Option (right to buy) | (1) | 12/18/2025 | Common Stock | 3,000 | $31.43 | D | |
| Employee Stock Option (right to buy) | (2) | 02/15/2027 | Common Stock | 2,100 | $20.53 | D | |
| Employee Stock Option (right to buy) | (3) | 03/02/2028 | Common Stock | 4,000 | $28.94 | D | |
| Employee Stock Option (right to buy) | (4) | 02/21/2029 | Common Stock | 19,850 | $21.88 | D | |
| Employee Stock Option (right to buy) | (5) | 02/20/2030 | Common Stock | 4,500 | $11.5 | D | |
| Employee Stock Option (right to buy) | (6) | 02/22/2031 | Common Stock | 5,000 | $19.18 | D | |
| Employee Stock Option (right to buy) | (7) | 02/22/2032 | Common Stock | 6,000 | $10.15 | D | |
| Employee Stock Option (right to buy) | (8) | 06/13/2032 | Common Stock | 8,000 | $2.44 | D | |
| Employee Stock Option (right to buy) | (9) | 02/15/2033 | Common Stock | 15,000 | $4.82 | D | |
| Restricted Stock Unit | (10) | (10) | Common Stock | 2,190 | $0(11) | D | |
| Employee Stock Option (right to buy) | (12) | 02/08/2034 | Common Stock | 12,250 | $18.3 | D | |
| Restricted Stock Unit | (13) | (13) | Common Stock | 4,750 | $0(11) | D | |
| Explanation of Responses: |
| 1. This option was granted on 12/18/2015 and 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter. |
| 2. This option was granted on 2/15/2017 and 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter. |
| 3. This option was granted on 3/2/2018 and 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter. |
| 4. This option was granted on 2/21/2019 and 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter. |
| 5. This option was granted on 2/20/2020 and 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter. |
| 6. This option was granted on 2/22/2021 and 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter. |
| 7. This option was granted on 2/22/2022 and 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter. |
| 8. This option was granted on 6/13/2022 and 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter. |
| 9. This option was granted on 2/15/2023 and 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter. |
| 10. The restricted stock units (RSUs) were granted on 2/15/2023 and vested as to 50% of the total shares one year after the date of grant and will vest 50% two years after the date of grant. |
| 11. Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. |
| 12. This option was granted on 2/8/2024 and 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter. |
| 13. The restricted stock units (RSUs) were granted on 2/8/2024 and will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. |
| Remarks: |
| Beth Smith | 01/13/2025 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||